The wind of innovation has come! Baiji, Junshi, Reding, Kangfang, etc. on the Hurun list!

Medicine Network October 22 - Hurun Research Institute recently released the 2020 Hurun Rich List, this is the Hurun Research Institute since 1999 for the 22nd consecutive release of the "Hurun Rich List."
in this list, the pharmaceutical sector jumped to the second largest number of entrepreneurs on the list, a total of more than 200 entrepreneurs on the list, of which the top 100 pharmaceutical entrepreneurs with a total wealth of more than 1.3 trillion yuan.
"Hurun Rich List" in the top 100 pharmaceutical entrepreneurs capital flow to leading enterprises accompanied by the transformation and innovation of the domestic pharmaceutical industry, many pharmaceutical innovation enterprises set foot on the capital market, resulting in a very obvious effect of wealth creation.
the hurun rich list has expanded by 32% this year, to an all-time high of 579, with 2,398 entrepreneurs with a wealth of more than 2 billion yuan.
In the field of medicine, the top 50 pharmaceutical entrepreneurs are regulars on the list of the major "rich list", of which Murray, Hengrui, Hansen, Eyre Ophthalmology and so on, corporate products and market movements are recognized and concerned by the capital market: Zhongranked 3rd, the wealth of 365 billion yuan 66-year-old Zhongwith 365 billion yuan in third place, is the year's largest black horse.
Zhong The increase in wealth is mainly due to the fact that its two companies, Wantay Bio and Farmer's Mountain Springs, have landed on the Shanghai and Hong Kong stock exchanges in the past year, and the two companies now have a market capitalization of more than 400 billion yuan, of which Farmer Shanquan has become the largest Chinese beverage company by market capitalization with a market capitalization of more than 350 billion yuan.
24th place, with a fortune of 120 billion yuan in 1991, Xu and Li Xiting founded Mei Rui Electronics.
2006, Murray Electronics listed in New York and became the first Chinese medical device company to list on the New York Stock Exchange.
time, Xu and Li Xiting were co-CEOs, and Xu was ranked 70th on Forbes' 2006 List of China's richest people, with a market capitalisation of about 20 billion yuan and personal assets of about 2.9 billion yuan.
Li Xiting ranked 27th, with a fortune of 115 billion yuan Meirui Medical for many years, has been focusing on monitoring devices, color super, in-body diagnostics and other medical equipment research and development and manufacturing, has been a large-scale domestic business, product system is very rich medical device enterprises.
currently, The market share of monitoring, defibrillation, anesthesia, blood cell analysis and other products of Meirui Medical is among the top six in the world and the top three in China.
Jiang Rensheng family ranked 20th, with a fortune of 135 billion yuan Zhifei biological main vaccine, biological products research and development, production, sales and promotion, is the domestic biological products industry large-scale backbone enterprises.
listed on the GEM on September 28, 2010, and its net profit has grown at an extraordinary rate in recent years, reaching 71.70 times that of 2016.
, the company's real controller, directly owns 51.14 percent of the company, and its holding wealth has grown by about 37.1 billion yuan since 2019.
Zhong Huixuan ranked 20th, with a fortune of 135 billion yuan on June 14, 2019, Hansen Pharmaceuticals listed on H shares, the same day the share price jumped 36.75 percent, closing at HK$19.50, with a market value of up to HK$111.3 billion to replace the Hong Kong stock "Drug King" of Pharmaceuticals Mingkangde.
recent years, Henson Pharmaceuticals' business performance has also continued to grow rapidly.
27th place, with a fortune of 115 billion yuan Hengrui Pharmaceuticals listed on the main board of the Shenzhen Stock Exchange on October 18, 2000.
20 years, the company's operating performance has continued to grow at a high rate, with operating income up about 47 times from 2000 and net profit up about 81 times.
first half of this year, Hengrui Pharmaceuticals achieved a net profit attributable to shareholders of listed companies of RMB2.662 billion, up 10.34% YoY.
Chen Bang ranked 41st, with a fortune of 100 billion yuan in 2009, Ayer Eye successfully listed.
from the "hospitals" of the first public hospitals to the global ophthalmology hospital group across Asia, Europe and the Americas, Chen Bang gradually held the key to building a medical empire in the sub-sector.
In addition, the wealth of Jiang Rensheng's family of Chongqing's "vaccine king" Zhifei Bio increased 1.6 times to 135 billion yuan, li Jianquan's family wealth of stable medical care, such as masks and other medical protection products manufacturers, increased nearly tenfold to 38 billion yuan, The ankang family wealth of Hualan Bio more than doubled to 52 billion yuan, and the wealth of Li Ge and Zhao Ning of Pharmaceutical Mingkang grew 63% to 49 billion yuan.
Industry innovation is becoming more concentrated Now China's pharmaceutical market is undergoing profound changes, medical insurance control fees, volume procurement, generic drug quality and efficacy consistent evaluation to promote enterprises to improve product quality level, a new round of medical insurance drug catalog adjustment and price negotiations are under way, disease diagnosis-related group collection and payment (DRGs) national pilot promotion and other policies, all promote the strength of pharmaceutical companies to innovation as the core driving force for development.
At the same time, the state in-depth promotion of medical reform, the introduction of centralized volume procurement, high-pressure anti-corruption in the pharmaceutical sector and other series of initiatives, local pharmaceutical enterprises are ushering in increased market competition, generic drug profits and other multiple challenges, which to a certain extent also reflects the traditional pharmaceutical industry chain homogenization of competition and lack of innovation, the industry to research and development innovation-driven demand is extremely urgent.
data show that A-share pharmaceutical and biological industry research and development costs have shown a normal upward trend.
-share pharmaceutical bio-enterprises had a median research and development expenses of about 0.69 billion yuan last year, up from 570 million yuan in 2018, while the median research and development expenses of A-share pharmaceutical companies (the proportion of total revenue) rose from 4.2% in 2018 to 4.7% in 2019.
even in the first half of this year, when the outbreak of neo-crown pneumonia hit, about 60% of pharmaceutical companies expected to spend more on research and development than in the same period last year.
It is worth noting that this list of 100 rich list, a number of biomedical innovation entrepreneurs among them, Baiji Shenzhou's Ou Leiqiang, Junshi Bio's Xiong Fengxiang, Xiong Jun's father and son, Meibo Pharmaceuticals' Guo Jianjun family, and then Ding Pharmaceutical's Du Ying, Kang Fang Bio's Xia Yu, No Cheng Jianhua's Shi Yigong, Zhao Renbin and his wife, Beida Pharmaceuticals' Ding Leming, etc., are the star enterprises in the field of biomedical innovation.
growth of entrepreneurs' personal wealth, no doubt fully reflects the market's focus on leading enterprises.
industry generally believes that the "Matthew effect" will be further highlighted as China deepens supply-side structural reforms in the past few years, promotes high-quality economic development, continues to optimize its economic structure, and rapidly concentrates on leading enterprises.
.